Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29787291 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16903398 | 0.92 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18084825 | 0.91 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL26621636 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13073094 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL21193740 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1966533 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16382728 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29787241 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL322321 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130907-A1 | ALKYLAMINE-CONTAINING SMALL MOLECULE DEGRADERS OF BCL6 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4604946-A1 | ALKYLAMINE-CONTAINING SMALL MOLECULE DEGRADERS OF BCL6 | Dana-Farber Cancer Institute, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| CN-120136863-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120025327-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-120025328-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119997949-A | BCL6 small molecule degradants containing alkylamines | 丹娜-法伯癌症研究院 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025059074-A1 | BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010080873-A1 | OXAZOLES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080873-A1 | OXAZOLES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| US-5387688-A | Intermediates for making analgesic N-phenyl-N-(3-OR1 -3-Me-4-piperidinyl)amides | GLAXO INC. (US) | 1995-02-07 | — | — | US | disclosed |
| US-5214148-A | Analgesic N-phenyl-N-(3-OR1 -3-ME-4-piperidinyl)amides | GLAXO INC. (US) | 1993-05-25 | — | — | US | disclosed |
| US-5130321-A | Analgesic n-phenyl-n-(3-or 1-3-me-4-piperidinyl)amides | GLAXO INC. (US) | 1992-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | SMN1; SMN2 850/4885NPC1 209/4885RAB9A 630/4885 |
| US-20260130907-A1 | ALKYLAMINE-CONTAINING SMALL MOLECULE DEGRADERS OF BCL6 | BCL6, BCL6B, BCL9L | SMN1; SMN2 3925/4885NPC1 119/4885RAB9A 744/4885 |
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | SMN1; SMN2 3079/4885NPC1 597/4885RAB9A 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.